Top_Dog_Pro_Trader,,2019-06-03 10:19:00,82.68,BMRN XBI IBB XLV SPX it was suppose to be a party exclusive invitation only It was huge short play on ValRox data but the data turned out to be decent BMRN thinks they can calibrate it even more Top rated CS analyst says the data supports accelerated approval Only a very modest adoption can lead to huge Revenue increases Keep in mind several analysts not so top notchwere supporting the hedge funds making big short bets now there trying to paint uncertainty in the data to exit short positions probably will go long Just 500 patients at 2M can add 1B to Revenue think about it and there are 117000 HemA possible patients per CS analyst
EstimizeAlerts,,2019-06-03 10:03:00,82.2,BMRN analysts on Estimize are expecting 4245 YoY EPS growth for Q2 up from 2308 in Q1 Reporting 0801 AMCestimizecomintrobmrncha
